fam91a1 Antibody

What is FAM91A1 and why is it significant in neurodevelopmental research?

FAM91A1 is a protein that forms a complex with TBC1D23, which is involved in endosome-to-Golgi trafficking. This protein has emerged as a potential PCH-associated gene, as depletion of FAM91A1 in zebrafish models results in developmental defects similar to those observed with TBC1D23 depletion, including smaller eyes, shorter distances between eyes, and enlarged ventricles. These developmental abnormalities recapitulate key features observed in PCH patients, suggesting FAM91A1's critical role in neuronal development . The significance of studying this protein lies in understanding converging mechanisms of PCH subtypes, potentially improving diagnosis and developing targeted treatment options for these rare neurodevelopmental disorders.

How do I select the appropriate FAM91A1 antibody for my research?

When selecting a FAM91A1 antibody, consider the specific region of the protein you aim to target. Based on structural studies, FAM91A1 has distinct domains that interact with different proteins. The N-terminus (residues 1-328) is particularly important as it directly interacts with TBC1D23 . If studying this interaction, choose antibodies that target epitopes outside this binding region to avoid interference with protein-protein interactions. Verify the antibody's reactivity with your species of interest, as FAM91A1 is conserved across various model organisms including human, mouse, zebrafish, tropical clawed frog, fruit fly, and nematode . Additionally, select antibodies validated for your specific application (western blot, immunofluorescence, immunoprecipitation) and confirm specificity through controls such as FAM91A1 knockout cells as demonstrated in previous studies .

What are the recommended fixation and permeabilization protocols for immunocytochemistry using FAM91A1 antibodies?

For optimal immunocytochemistry results when studying FAM91A1, which localizes to punctate structures in cells, use paraformaldehyde fixation (4%) for 15-20 minutes at room temperature. Since FAM91A1 functions in endosome-to-Golgi trafficking and co-localizes with TBC1D23 and Golgi markers, a careful permeabilization protocol is essential. Use 0.1-0.2% Triton X-100 for 5-10 minutes for initial studies. If studying FAM91A1's co-localization with TGN markers like golgin-97, as demonstrated in previous research, saponin (0.05-0.1%) might provide more gentle permeabilization that better preserves membrane structures . When conducting co-localization studies with Golgi markers, a mild fixation and permeabilization approach is crucial to maintain the integrity of these structures while ensuring antibody accessibility.

How can I optimize FAM91A1 antibody usage for studying its interaction with TBC1D23?

Optimizing antibody usage for studying the FAM91A1-TBC1D23 interaction requires careful consideration of epitope selection. The crystal structure reveals that TBC1D23 binds to FAM91A1 via a Z-shaped conformation at a conserved surface, with key FAM91A1 residues (R61, K190/D194, D198) being critical for this interaction . Select antibodies targeting regions away from these residues to avoid disrupting the interaction. For co-immunoprecipitation experiments, use a sequential approach: first immunoprecipitate with an antibody against one protein (e.g., FAM91A1) and then probe for the interacting partner (TBC1D23) on western blots. Include appropriate controls such as:

When performing proximity ligation assays to visualize interactions in situ, use antibodies raised in different species to enable species-specific secondary antibody recognition, and include controls with single antibodies to establish background signal levels .

What are the validated protocols for studying FAM91A1 localization in relation to endosomal trafficking?

To study FAM91A1 localization in endosomal trafficking, implement a multi-channel immunofluorescence approach combined with live-cell imaging. Based on published research, FAM91A1 forms punctate structures that extensively colocalize with TBC1D23 in live cells . For fixed-cell immunofluorescence:

• Fix cells with 4% paraformaldehyde (15 minutes, room temperature)

• Permeabilize with 0.1% Triton X-100 (10 minutes, room temperature)

• Block with 3% BSA in PBS (1 hour, room temperature)

• Incubate with primary antibodies against FAM91A1 and markers for:

  • TGN (e.g., golgin-97, GRIP proteins)

  • Endosomes (e.g., Rab5, Rab7, or EEA1)

  • Cargo proteins (e.g., KIAA0319L)

• Apply appropriate secondary antibodies and counterstain nuclei with DAPI

For live-cell imaging, utilize GFP-FAM91A1 and mCherry-TBC1D23 constructs as demonstrated in previous studies that revealed their dynamic colocalization . Complement these approaches with proximity ligation assays to confirm direct interaction between FAM91A1 and TBC1D23 in cells, particularly at TGN-endosome interfaces.

How can I troubleshoot non-specific binding issues with FAM91A1 antibodies?

• Validation with knockout controls: Generate FAM91A1 knockout cells using CRISPR-Cas9 as described in previous studies; a complete absence of signal in these cells confirms antibody specificity .

• Peptide competition assay: Pre-incubate the antibody with excess synthetic peptide corresponding to the epitope (such as FAM91A1 AA 127-155 for certain antibodies) . Disappearance of signal indicates specificity.

• Cross-reactivity assessment: Test the antibody against recombinant FAM91A1 fragments to identify potential cross-reactivity with homologous proteins.

• Optimization of blocking conditions:

• Titrate antibody concentration: Test a dilution series to identify the optimal concentration that maximizes specific signal while minimizing background.

How can FAM91A1 antibodies be utilized in zebrafish models to study PCH-like phenotypes?

FAM91A1 antibodies can be valuable tools in zebrafish models for PCH research, particularly when studying developmental defects similar to those observed with TBC1D23 depletion. Based on recent findings, depletion of FAM91A1 in zebrafish results in smaller eyes, shorter inter-eye distance, enlarged fourth ventricle, and reduced midbrain size . To effectively employ antibodies in this context:

• Whole-mount immunohistochemistry: Use FAM91A1 antibodies compatible with zebrafish tissue to visualize protein expression patterns throughout development, particularly in neural tissues. This allows correlation of protein localization with the developmental defects observed in morpholino-injected embryos.

• Section immunohistochemistry: For detailed analysis of brain structures, particularly the cerebellum and pons regions affected in PCH, perform antibody staining on cryosections or paraffin sections of zebrafish embryos at different developmental stages.

• Co-staining approach: Combine FAM91A1 antibodies with neuronal markers such as HuC-GFP (an early marker of pan-neuronal cells) to assess the relationship between FAM91A1 expression and neuronal development . Similarly, use motor neuron markers like those in the Tg[Hb9:GFP]ml2 transgenic line to examine CaP motor neuron morphology in relation to FAM91A1 expression .

• Rescue experiments: In FAM91A1-depleted zebrafish, perform rescue experiments by introducing wild-type or mutant FAM91A1 constructs, then use antibodies to confirm expression and localization of the introduced protein.

What methodologies are recommended for studying FAM91A1-dependent KIAA0319L trafficking using antibodies?

Studying FAM91A1-dependent KIAA0319L trafficking requires a comprehensive approach combining cellular, biochemical, and imaging techniques. KIAA0319L, a protein involved in axonal growth, depends on FAM91A1 for proper endosome-to-Golgi trafficking . To investigate this process:

• Internalization assay: Use antibodies against the extracellular region of KIAA0319L to track its internalization and subsequent trafficking. After labeling surface KIAA0319L, allow internalization for defined time periods (2-60 minutes) and fix cells at different timepoints to visualize trafficking progression .

• Colocalization analysis: Perform triple immunofluorescence using antibodies against:

  • FAM91A1

  • KIAA0319L

  • Golgi marker (e.g., golgin-97)

  Quantify colocalization using Pearson's correlation coefficient or Manders' overlap coefficient. In FAM91A1 knockout cells, KIAA0319L shows dispersed distribution with significantly reduced colocalization with golgin-97 .

• Protein stability assessment: Monitor KIAA0319L protein levels by western blot in control, FAM91A1-knockout, and rescue conditions. Quantification should include normalization to housekeeping proteins and statistical analysis. Previous research has shown that FAM91A1 deletion leads to decreased KIAA0319L protein levels due to missorting and lysosomal degradation .

• Rescue experiments: Transfect FAM91A1-knockout cells with wild-type FAM91A1 or binding-deficient mutants (R61A, K190A/D194A, D198R) and assess KIAA0319L localization and protein levels . This approach can determine the specific contribution of the FAM91A1-TBC1D23 interaction to KIAA0319L trafficking.

How can I analyze FAM91A1 mutations identified in PCH patients using antibody-based approaches?

Analyzing FAM91A1 mutations associated with PCH requires multiple antibody-based approaches to assess protein expression, localization, and function. While mutations in WDR11 (a subunit of the FAM91A1 complex) have been found in patients with PCH-like symptoms, mutations in FAM91A1 itself could potentially disrupt endosomal trafficking and contribute to PCH pathology . To analyze such mutations:

• Expression analysis: Use western blotting with FAM91A1 antibodies to determine if mutations affect protein stability or expression levels. Compare expression in patient-derived cells (if available) or in cells transfected with mutant constructs to wild-type controls.

• Subcellular localization: Employ immunofluorescence microscopy to assess if mutations alter FAM91A1's punctate distribution pattern or its colocalization with TBC1D23 and Golgi markers . Quantify changes in localization patterns using colocalization coefficients and distribution analysis.

• Interaction studies:

  • Co-immunoprecipitation: Test if mutations disrupt the interaction with TBC1D23 by immunoprecipitating mutant FAM91A1 and blotting for TBC1D23

  • Proximity ligation assay: Visualize and quantify in situ interactions between mutant FAM91A1 and its binding partners

• Functional assessment: Evaluate the ability of mutant FAM91A1 to rescue trafficking defects in knockout cells by analyzing KIAA0319L localization and stability . This approach directly tests if patient mutations are likely pathogenic by disrupting FAM91A1 function.

What are the optimal conditions for immunoprecipitation of FAM91A1 and its binding partners?

Optimizing immunoprecipitation (IP) conditions for FAM91A1 and its binding partners requires careful consideration of buffer composition, antibody selection, and experimental controls. Based on the structural and functional studies of the FAM91A1-TBC1D23 complex:

• Lysis buffer optimization:

  • Start with a mild buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100

  • Include protease inhibitors: Complete protease inhibitor cocktail

  • Add phosphatase inhibitors if studying phosphorylation-dependent interactions: 10 mM NaF, 1 mM Na₃VO₄

  • Consider testing different detergent concentrations as the FAM91A1-TBC1D23 interaction occurs with a binding affinity of 1.15 ± 0.16 μM

• Antibody selection and immobilization:

  • Choose antibodies targeting regions away from the interaction interface (avoid epitopes containing R61, K190/D194, D198 residues of FAM91A1)

  • For weak or transient interactions, consider chemical crosslinking (e.g., DSP or formaldehyde) prior to cell lysis

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Washing conditions:

  • Initial washes: Use lysis buffer to remove weakly bound proteins

  • Stringent washes: Increase salt concentration (up to 300 mM NaCl) for subsequent washes

  • Final washes: Use buffer without detergent to remove residual detergent before elution

• Elution methods:

  • Denaturing: SDS sample buffer at 95°C (most common)

  • Native: Excess antigen peptide competition (useful for downstream functional assays)

  • Acidic glycine buffer (pH 2.5-3.0) followed by immediate neutralization

• Controls:

  • Input lysate (5-10% of IP input)

  • IgG control (same species as the IP antibody)

  • FAM91A1 knockout lysate

  • Binding-deficient mutants (e.g., TBC1D23 Y530A, R531D, F537A or FAM91A1 R61A, K190A/D194A, D198R)

How can I design experiments to specifically study the FAM91A1-TBC1D23 interaction interface using antibodies?

Designing experiments to study the FAM91A1-TBC1D23 interaction interface requires approaches that can directly interrogate the binding surface or assess the functional consequences of disrupting specific contact points. Based on the crystal structure showing that TBC1D23 binds to a conserved surface on FAM91A1 via a Z-shaped conformation :

• Epitope mapping and antibody blocking:

  • Generate antibodies against specific peptides spanning the interaction interface

  • Test whether these antibodies block the interaction in pull-down assays

  • Use in live cells to determine functional consequences of blocking specific interfaces

• Mutation-specific antibodies:

  • Develop antibodies that specifically recognize wild-type or mutant forms of the interaction interface

  • These can be used to distinguish between properly formed and disrupted complexes

• Competitive peptide approach:

  • Synthesize peptides corresponding to the TBC1D23 peptide (residues 514-543) that binds FAM91A1

  • Introduce these peptides into cells to competitively inhibit the interaction

  • Use antibodies against FAM91A1 and TBC1D23 to assess changes in localization and function

• FRET/BRET-based interaction studies:

  • Create fusion constructs with fluorescent or bioluminescent tags

  • Measure energy transfer as an indicator of protein proximity

  • Introduce specific mutations (Y530A, R531D, F537A in TBC1D23 or R61A, K190A/D194A, D198R in FAM91A1) to disrupt the interaction

  • Validate using antibodies in parallel experiments

• Proximity ligation assays (PLA):

  • Use specific antibodies against FAM91A1 and TBC1D23

  • PLA signal will only be generated when proteins are in close proximity (<40 nm)

  • Compare wild-type vs. mutant proteins to quantify the impact of specific mutations on the interaction interface

What methods can be used to validate FAM91A1 antibody specificity for structural and functional studies?

Validating FAM91A1 antibody specificity is critical for structural and functional studies, especially when investigating protein-protein interactions and trafficking functions. Comprehensive validation should include:

• Genetic validation approaches:

  • CRISPR/Cas9 knockout cells: Generate complete FAM91A1 knockout cell lines as negative controls. The absence of signal in these cells confirms antibody specificity

  • siRNA or shRNA knockdown: Demonstrate reduced signal intensity proportional to knockdown efficiency

  • Morpholino studies in zebrafish: Correlate antibody signal reduction with the >60% reduction in FAM91A1 mRNA levels observed in morpholino-injected zebrafish

• Biochemical validation:

  • Western blot analysis showing a single band at the expected molecular weight (~91 kDa)

  • Immunoprecipitation followed by mass spectrometry to confirm the pulled-down protein is FAM91A1

  • Pre-absorption with recombinant FAM91A1 or immunizing peptide to eliminate specific binding

• Domain-specific validation:

  • Test antibody recognition against truncated FAM91A1 constructs (e.g., FAM91A1 N-terminal domain residues 1-328)

  • Compare antibody binding to wild-type vs. mutant proteins (e.g., R61A, K190A/D194A, D198R mutants)

  • Assess cross-reactivity with related family members

• Species cross-reactivity:

  • Test reactivity across species (human, mouse, zebrafish) since FAM91A1 is conserved across these organisms

  • Validate in tissue/cells from multiple species if using the antibody for comparative studies

• Application-specific validation:

  • For immunofluorescence: Compare localization pattern to GFP-tagged FAM91A1 expressed in live cells

  • For proximity studies: Use positive and negative controls with known interaction partners

  • For trafficking studies: Confirm ability to detect changes in localization upon disruption of trafficking (e.g., Brefeldin A treatment)

How can FAM91A1 antibodies be employed to study axon guidance mechanisms in neuronal cultures?

FAM91A1 antibodies can be valuable tools for investigating axon guidance mechanisms, particularly given the role of FAM91A1 in trafficking KIAA0319L, a protein involved in axonal growth . To effectively employ these antibodies in neuronal culture studies:

• Developmental time course analysis:

  • Culture primary neurons (cortical, hippocampal, or cerebellar) for varying durations (1-21 days)

  • Fix and immunostain with FAM91A1 antibodies at different developmental stages

  • Co-stain with axonal markers (Tau or neurofilament) and dendritic markers (MAP2)

  • Quantify FAM91A1 expression and localization changes during neuronal maturation and correlate with axon development

• Growth cone localization studies:

  • Focus on growth cones using high-resolution microscopy

  • Triple-label with FAM91A1 antibodies, TBC1D23 antibodies, and growth cone markers

  • Assess whether FAM91A1 localizes to specific subdomains of the growth cone (central domain vs. peripheral domain)

  • Correlate with growth cone dynamics using live imaging of fluorescently tagged FAM91A1

• Functional perturbation:

  • Transfect neurons with siRNA against FAM91A1 or expression vectors for binding-deficient mutants

  • Analyze axon length, branching, and pathfinding using morphometric analysis

  • The phenotypes should mirror those observed in zebrafish models, where FAM91A1 depletion led to abnormal CaP motor neuron morphology and reduced axon length (67% compared to control)

• Cargo trafficking visualization:

  • Use FAM91A1 antibodies in conjunction with KIAA0319L antibodies

  • Perform live trafficking assays to track KIAA0319L movement in axons

  • Compare trafficking dynamics in control neurons versus neurons with FAM91A1 knockdown or expressing binding-deficient mutants

What protocols are recommended for using FAM91A1 antibodies in brain tissue sections from PCH model organisms?

Using FAM91A1 antibodies in brain tissue sections from PCH model organisms requires specialized protocols to enhance sensitivity and specificity. Based on the known involvement of FAM91A1 in PCH-like developmental defects:

• Tissue preparation optimization:

  • Perfusion fixation: For rodent models, use 4% paraformaldehyde in PBS

  • Post-fixation: 2-4 hours for embryonic tissue, 12-24 hours for adult tissue

  • For zebrafish: Consider whole-mount fixation for embryos or larvae

  • Section thickness: 10-20 μm for fluorescence microscopy, 5-8 μm for brightfield

• Antigen retrieval methods:

  • Heat-induced epitope retrieval: 10 mM sodium citrate buffer (pH 6.0) at 95°C for 15-20 minutes

  • Enzymatic retrieval: Proteinase K (10 μg/ml) for 5-10 minutes at room temperature

  • Compare multiple methods to determine optimal signal-to-noise ratio for FAM91A1 detection

• Signal amplification strategies:

  • Tyramide signal amplification (TSA) to enhance detection of low-abundance proteins

  • Biotin-streptavidin systems for chromogenic detection

  • These approaches may be particularly important when examining structures affected in PCH, such as the cerebellum and pons

• Multiplex immunostaining panel:

  • FAM91A1 + TBC1D23 + cell-type specific markers (depending on research question)

  • For developmental studies: Include markers for neuronal progenitors, migrating neurons, and mature neurons

  • For cerebellar studies: Include markers for Purkinje cells, granule cells, and Bergmann glia

  • Recommended controls: FAM91A1-depleted tissue (e.g., from morpholino-injected zebrafish)

• Imaging and quantification:

  • Use confocal microscopy for cellular resolution

  • Z-stack acquisition for three-dimensional analysis of protein distribution

  • Quantify FAM91A1 expression levels in specific brain regions affected in PCH

  • Compare control to disease models, focusing on regions showing developmental defects (midbrain, cerebellum)

How can I design experiments to investigate FAM91A1's role in convergent mechanisms of PCH subtypes?

Designing experiments to investigate FAM91A1's role in convergent mechanisms of PCH subtypes requires a comprehensive approach that spans molecular, cellular, and organismal levels of analysis. Given that impaired endosomal trafficking has been identified as a convergent mechanism for many PCH subtypes :

• Comparative analysis across PCH models:

  • Use FAM91A1 antibodies to assess protein expression and localization in:

    • TBC1D23 mutant models

    • WDR11 mutant models

    • Other established PCH models (e.g., EXOSC3, TSEN54)

  • Compare subcellular localization patterns to identify common trafficking defects

  • Quantify colocalization with endosomal and Golgi markers across different models

• Cargo trafficking assessment:

  • Examine trafficking of KIAA0319L across different PCH models

  • Investigate other potential cargo proteins that might be commonly affected

  • Use pulse-chase experiments with FAM91A1 antibodies to track protein movement in control vs. PCH model cells

• Molecular pathway integration:

  • Perform immunoprecipitation with FAM91A1 antibodies followed by mass spectrometry

  • Compare interactomes across different PCH models to identify common molecular hubs

  • Use proximity labeling approaches (BioID, APEX) to map the local protein environment of FAM91A1 in health and disease states

• Rescue experiments across models:

  • Test if overexpression of FAM91A1 can rescue phenotypes in TBC1D23 mutant models

  • Assess if enhancing endosome-to-Golgi trafficking pathways can ameliorate defects across different PCH models

  • Design a systematic rescue experiment matrix:

• In vivo developmental analysis:

  • Use FAM91A1 antibodies in conjunction with neurodevelopmental markers in zebrafish models

  • Compare developmental trajectories of brain structures affected in PCH

  • Quantify neuronal migration, axon outgrowth, and circuit formation

  • Focus on structures showing developmental defects in FAM91A1-depleted zebrafish, such as reduced midbrain size and abnormal motor neuron morphology